These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38016690)

  • 1. Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.
    Takahashi K; Usuzaki T; Inamori R
    Korean J Radiol; 2023 Dec; 24(12):1303-1305. PubMed ID: 38016690
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma".
    Park YW; Han K; Kim SH
    Korean J Radiol; 2023 Dec; 24(12):1306-1308. PubMed ID: 38016689
    [No Abstract]   [Full Text] [Related]  

  • 3. Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI.
    Gao J; Liu Z; Pan H; Cao X; Kan Y; Wen Z; Chen S; Wen M; Zhang L
    J Magn Reson Imaging; 2024 May; 59(5):1655-1664. PubMed ID: 37555723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.
    Zhang L; Wang R; Gao J; Tang Y; Xu X; Kan Y; Cao X; Wen Z; Liu Z; Cui S; Li Y
    Eur Radiol; 2024 Jan; 34(1):391-399. PubMed ID: 37553486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial for "Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI".
    Gumeler E; Karli Oguz K
    J Magn Reson Imaging; 2024 May; 59(5):1665-1666. PubMed ID: 37306402
    [No Abstract]   [Full Text] [Related]  

  • 6. Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study.
    Park YW; Park KS; Park JE; Ahn SS; Park I; Kim HS; Chang JH; Lee SK; Kim SH
    Korean J Radiol; 2023 Feb; 24(2):133-144. PubMed ID: 36725354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.
    Fortin Ensign SP; Jenkins RB; Giannini C; Sarkaria JN; Galanis E; Kizilbash SH
    Neuro Oncol; 2023 Jan; 25(1):28-36. PubMed ID: 35973817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    Xi S; Huang Q; Zeng J
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):125-130. PubMed ID: 38175671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
    Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
    Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH-mutant astrocytoma with an evolutional progression to CDKN2A/B homozygous deletion and NTRK fusion during recurrence: A case report.
    Kirishima M; Akahane T; Higa N; Suzuki S; Ueno S; Yonezawa H; Uchida H; Hanaya R; Yoshimoto K; Shimajiri S; Kitazono I; Tanimoto A
    Pathol Res Pract; 2022 Nov; 239():154163. PubMed ID: 36265224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 12. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
    Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
    Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
    Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    Yokoda RT; Cobb WS; Yong RL; Crary JF; Viapiano MS; Walker JM; Umphlett M; Tsankova NM; Richardson TE
    J Neuropathol Exp Neurol; 2023 Sep; 82(10):845-852. PubMed ID: 37550258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
    Marker DF; Pearce TM
    Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.
    Galbraith K; Garcia M; Wei S; Chen A; Schroff C; Serrano J; Pacione D; Placantonakis DG; William CM; Faustin A; Zagzag D; Barbaro M; Eibl MDPGP; Shirahata M; Reuss D; Tran QT; Alom Z; von Deimling A; Orr BA; Sulman EP; Golfinos JG; Orringer DA; Jain R; Lieberman E; Feng Y; Snuderl M
    Neuro Oncol; 2024 Jun; 26(6):1042-1051. PubMed ID: 38243818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral heterogeneity of CDKN2A deletions in IDH-mutant astrocytoma.
    Masui K; Onizuka H; Muragaki Y; Kawamata T; Kurata A; Komori T
    Brain Tumor Pathol; 2024 Apr; 41(2):92-95. PubMed ID: 38597998
    [No Abstract]   [Full Text] [Related]  

  • 19. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
    Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
    Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
    Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
    Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.